Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Zevra Therapeutics (ZVRA) stock in plain English

Free brief · no signupStart here
ZVRAPublished Nov 15, 2026
Zevra Therapeutics Inc
Healthcare · Biotechnology
Develops and sells prescription pharmaceutical therapies for rare genetic diseases.
Assets:
MIPLYFFA medicationFDA-approved treatment for Niemann-Pick disease type C
OLPRUVA therapyCommercial prescription drug for urea cycle disorders
Rare disease pipelineClinical development assets targeting genetic neurological conditions
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

92
OPS ScoreOperating finances
Latest quote
-2.26%$9.07
$539.70M
7.6×
$147.86M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ZVRA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Zevra Therapeutics (ZVRA) do?

Zevra Therapeutics Inc (ZVRA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops and sells prescription pharmaceutical therapies for rare genetic diseases. Commercializes rare disease therapies, holding the first approved treatment for Niemann-Pick disease type C. It is worth $539.70M on the market and sold $147.86M over the last year.

Market cap
$539.70M
P/E ratio
7.6×
Annual sales
$147.86M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 15, 2026

Brands and businesses behind ZVRA

  • MIPLYFFA: An oral capsule therapy sold to healthcare providers for treating Niemann-Pick disease type C.
  • OLPRUVA: An oral suspension kit sold through specialty pharmacies to treat urea cycle disorders.

ZVRA’s flags, in plain English

Each flag is a number from Zevra Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Stupid Cash

Can pay this year's bills 5.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 50.7%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Heavily Shorted

11.2% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about ZVRA

How big is Zevra Therapeutics?

Zevra Therapeutics’ market cap is $539.70M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $147.86M: what customers paid the company over the last year, before any costs.

What is ZVRA’s P/E ratio?

ZVRA’s P/E ratio is 7.6×. Investors pay about 7.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ZVRA?

Strict European regulatory hurdles currently block commercial distribution of the primary drug across European Union markets. That is one risk on Zevra Therapeutics’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Zevra Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ZVRA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card